Clinical Trials Logo

Adenocarcinoma - GEJ clinical trials

View clinical trials related to Adenocarcinoma - GEJ.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04014075 Completed - Clinical trials for Adenocarcinoma - GEJ

DS-8201a in HER2-positive Gastric Cancer That Cannot Be Surgically Removed or Has Spread (DESTINY-Gastric02)

Start date: November 26, 2019
Phase: Phase 2
Study type: Interventional

This study will find out if trastuzumab deruxtecan is safe and works for participants with gastric or gastroesophageal junction cancer. They must have human epidermal growth factor receptor 2 (HER2)-positive gastric or gastro-esophageal junction (GEJ) cancer: - that cannot be removed surgically - that has moved to other parts of the body - that got worse during or after treatment that included trastuzumab The study will enroll about 80 participants. Sites will be in North America and the European Union.